Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 125

1.

Chronic Adolescent CDPPB Treatment Alters Short-Term, but not Long-Term, Glutamatergic Receptor Expression.

Lum JS, Millard SJ, Frank E, Matosin N, Huang XF, Ooi L, Newell KA.

Neurochem Res. 2018 Jun 23. doi: 10.1007/s11064-018-2584-x. [Epub ahead of print]

PMID:
29936568
2.

Functional analysis of schizophrenia genes using GeneAnalytics program and integrated databases.

Sundararajan T, Manzardo AM, Butler MG.

Gene. 2018 Jan 30;641:25-34. doi: 10.1016/j.gene.2017.10.035. Epub 2017 Oct 13.

PMID:
29032150
3.

Role of mGlu5 Receptors and Inhibitory Neurotransmission in M1 Dependent Muscarinic LTD in the Prefrontal Cortex: Implications in Schizophrenia.

Ghoshal A, Moran SP, Dickerson JW, Joffe ME, Grueter BA, Xiang Z, Lindsley CW, Rook JM, Conn PJ.

ACS Chem Neurosci. 2017 Oct 18;8(10):2254-2265. doi: 10.1021/acschemneuro.7b00167. Epub 2017 Aug 9.

PMID:
28679049
4.

Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders.

Foster DJ, Conn PJ.

Neuron. 2017 May 3;94(3):431-446. doi: 10.1016/j.neuron.2017.03.016. Review.

5.

Effects of common GRM5 genetic variants on cognition, hippocampal volume and mGluR5 protein levels in schizophrenia.

Matosin N, Newell KA, Quidé Y, Andrews JL, Teroganova N, Green MJ, Fernandez F.

Brain Imaging Behav. 2018 Apr;12(2):509-517. doi: 10.1007/s11682-017-9712-0.

PMID:
28405888
6.

Difluorocyclobutylacetylenes as positive allosteric modulators of mGluR5 with reduced bioactivation potential.

Degnan AP, Maxwell D, Balakrishnan A, Brown JM, Easton A, Gulianello M, Hanumegowda U, Hill-Drzewi M, Miller R, Santone KS, Senapati A, Shields EE, Sivarao DV, Westphal R, Whiterock VJ, Zhuo X, Bronson JJ, Macor JE.

Bioorg Med Chem Lett. 2016 Dec 15;26(24):5871-5876. doi: 10.1016/j.bmcl.2016.11.014. Epub 2016 Nov 9.

PMID:
27856084
7.

Metabotropic glutamate receptor 5 neuroimaging in schizophrenia.

Akkus F, Treyer V, Ametamey SM, Johayem A, Buck A, Hasler G.

Schizophr Res. 2017 May;183:95-101. doi: 10.1016/j.schres.2016.11.008. Epub 2016 Nov 12.

PMID:
27847228
8.

Neurodevelopmental Expression Profile of Dimeric and Monomeric Group 1 mGluRs: Relevance to Schizophrenia Pathogenesis and Treatment.

Lum JS, Fernandez F, Matosin N, Andrews JL, Huang XF, Ooi L, Newell KA.

Sci Rep. 2016 Oct 10;6:34391. doi: 10.1038/srep34391.

9.

Altered expression of schizophrenia-related genes in mice lacking mGlu5 receptors.

Luoni A, Gass P, Brambilla P, Ruggeri M, Riva MA, Inta D.

Eur Arch Psychiatry Clin Neurosci. 2018 Feb;268(1):77-87. doi: 10.1007/s00406-016-0728-z. Epub 2016 Aug 31.

PMID:
27581816
10.

Oxazolidinone-based allosteric modulators of mGluR5: Defining molecular switches to create a pharmacological tool box.

Huang H, Degnan AP, Balakrishnan A, Easton A, Gulianello M, Huang Y, Matchett M, Mattson G, Miller R, Santone KS, Senapati A, Shields EE, Sivarao DV, Snyder LB, Westphal R, Whiterock VJ, Yang F, Bronson JJ, Macor JE.

Bioorg Med Chem Lett. 2016 Sep 1;26(17):4165-9. doi: 10.1016/j.bmcl.2016.07.065. Epub 2016 Jul 28.

PMID:
27496211
11.

Multiprobe molecular imaging of an NMDA receptor hypofunction rat model for glutamatergic dysfunction.

Kosten L, Verhaeghe J, Verkerk R, Thomae D, De Picker L, Wyffels L, Van Eetveldt A, Dedeurwaerdere S, Stroobants S, Staelens S.

Psychiatry Res Neuroimaging. 2016 Feb 28;248:1-11. doi: 10.1016/j.pscychresns.2016.01.013. Epub 2016 Jan 12.

PMID:
26803479
12.

An mGlu5-Positive Allosteric Modulator Rescues the Neuroplasticity Deficits in a Genetic Model of NMDA Receptor Hypofunction in Schizophrenia.

Balu DT, Li Y, Takagi S, Presti KT, Ramikie TS, Rook JM, Jones CK, Lindsley CW, Conn PJ, Bolshakov VY, Coyle JT.

Neuropsychopharmacology. 2016 Jul;41(8):2052-61. doi: 10.1038/npp.2016.2. Epub 2016 Jan 7.

13.
14.

Preliminary investigation of 6,7-dihydropyrazolo[1,5-a]pyrazin-4-one derivatives as a novel series of mGlu5 receptor positive allosteric modulators with efficacy in preclinical models of schizophrenia.

Conde-Ceide S, Alcázar J, Alonso de Diego SA, López S, Martín-Martín ML, Martínez-Viturro CM, Pena MA, Tong HM, Lavreysen H, Mackie C, Bridges TM, Daniels JS, Niswender CM, Jones CK, Macdonald GJ, Steckler T, Conn PJ, Stauffer SR, Lindsley CW, Bartolomé-Nebreda JM.

Bioorg Med Chem Lett. 2016 Jan 15;26(2):429-434. doi: 10.1016/j.bmcl.2015.11.098. Epub 2015 Nov 28.

15.

Loss of Metabotropic Glutamate Receptor 5 Function on Peripheral Benzodiazepine Receptor in Mice Prenatally Exposed to LPS.

Arsenault D, Coulombe K, Zhu A, Gong C, Kil KE, Choi JK, Poutiainen P, Brownell AL.

PLoS One. 2015 Nov 4;10(11):e0142093. doi: 10.1371/journal.pone.0142093. eCollection 2015.

16.

Combined behavioral studies and in vivo imaging of inflammatory response and expression of mGlu5 receptors in schnurri-2 knockout mice.

Choi JK, Zhu A, Jenkins BG, Hattori S, Kil KE, Takagi T, Ishii S, Miyakawa T, Brownell AL.

Neurosci Lett. 2015 Nov 16;609:159-64. doi: 10.1016/j.neulet.2015.10.037. Epub 2015 Oct 23.

PMID:
26483320
17.

Development of Novel, CNS Penetrant Positive Allosteric Modulators for the Metabotropic Glutamate Receptor Subtype 1 (mGlu1), Based on an N-(3-Chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide Scaffold, That Potentiate Wild Type and Mutant mGlu1 Receptors Found in Schizophrenics.

Garcia-Barrantes PM, Cho HP, Niswender CM, Byers FW, Locuson CW, Blobaum AL, Xiang Z, Rook JM, Conn PJ, Lindsley CW.

J Med Chem. 2015 Oct 22;58(20):7959-71. doi: 10.1021/acs.jmedchem.5b00727. Epub 2015 Oct 8.

18.

Preclinical Evaluation and Quantification of 18F-FPEB as a Radioligand for PET Imaging of the Metabotropic Glutamate Receptor 5.

de Laat B, Leurquin-Sterk G, Celen S, Bormans G, Koole M, Van Laere K, Casteels C.

J Nucl Med. 2015 Dec;56(12):1954-9. doi: 10.2967/jnumed.115.162636. Epub 2015 Sep 24.

19.

Shining Light on an mGlu5 Photoswitchable NAM: A Theoretical Perspective.

Dalton JA, Lans I, Rovira X, Malhaire F, Gómez-Santacana X, Pittolo S, Gorostiza P, Llebaria A, Goudet C, Pin JP, Giraldo J.

Curr Neuropharmacol. 2016;14(5):441-54.

20.

Shifting towards a model of mGluR5 dysregulation in schizophrenia: Consequences for future schizophrenia treatment.

Matosin N, Fernandez-Enright F, Lum JS, Newell KA.

Neuropharmacology. 2017 Mar 15;115:73-91. doi: 10.1016/j.neuropharm.2015.08.003. Epub 2015 Sep 6. Review.

PMID:
26349010

Supplemental Content

Loading ...
Support Center